Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma.
Jedd D WolchokVanna Chiarion SileniRene GonzalezJean-Jacques GrobPiotr Lukasz RutkowskiChristopher D LaoC Lance CoweyDirk SchadendorfJohn WagstaffReinhard DummerPier Francesco FerrucciMichael SmylieMarcus O ButlerAndrew HillIvan Marquez-RodasJohn B A G HaanenMassimo GuidoboniMichele MaioPatrick SchöffskiMatteo S CarlinoCeleste LebbèGrant A McArthurPaolo Antonio AsciertoGregory A DanielsGeorgina V LongTuba BasCorey RitchingsJames M G LarkinFrank Stephen HodiPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
These 6.5-year CheckMate 067 results, which include the longest median OS in a phase III melanoma trial reported to date and the first report of MSS, showed durable, improved clinical outcomes with nivolumab plus ipilimumab or nivolumab versus ipilimumab in patients with advanced melanoma and, in descriptive analyses, with the combination over nivolumab monotherapy.